2Edmond MB,Wallace SE,McClish DK,et al.Nosocomial bloodstream infections in United States hospitals:a threeyear analysis[J].Clin Infect Dis,1999,29(2):239-44.
3Kontoyiannis PD,Lewis RE.Antifungal drug resistance of pathogenic fungi[J].Lancet,2002,359(9312):1135-1144.
4Fernadez-Torres B,Inza I,Guarro J.Comparison of in vitro antifungal susceptibilities of conidia and hyphae of dermatophytes with thick-wall macroconidia. Antimicrob. Agents Chemother,2003 ,47: 3371-3372.
6Vanden Bossche H,Ausma J,Bohets H,et al.The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother,2004 ,48: 3272-3278.
7Meletiadis J,Mouton JW,Meis JF,et al.In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother,2003 ,47: 106-117.
8Ortoneda M,Capilla J,Pastor FJ,et al.In vitro interactions of approved and novel drugs against Paecilomyces spp. Antimicrob Agents Chemother,2004, 48: 2727-2729.
